	US 11,938,154 B2
	Compositions and methods for treating and/or preventing sepsis and/or inflammatory conditions
Hongkuan Fan, Charleston, SC (US); Andrew Goodwin, Mount Pleasant, SC (US); Perry V. Halushka, Charleston, SC (US); James A Cook, Mount Pleasant, SC (US); and Yue Zhou, San Francisco, CA (US)
Assigned to MUSC Foundation for Research Development, Charleston, SC (US)
Appl. No. 16/959,030
Filed by MUSC Foundation for Research Development, Charleston, SC (US)
PCT Filed Feb. 27, 2019, PCT No. PCT/US2019/019822 § 371(c)(1), (2) Date Jun. 29, 2020, PCT Pub. No. WO2019/168977, PCT Pub. Date Sep. 6, 2019.
Claims priority of provisional application 62/635,913, filed on Feb. 27, 2018.
Prior Publication US 2020/0390822 A1, Dec. 17, 2020
Int. Cl. A61K 35/44 (2015.01); A61K 38/19 (2006.01); A61P 11/00 (2006.01); A61P 31/04 (2006.01)

CPC A61K 35/44 (2013.01) [A61K 38/195 (2013.01); A61P 11/00 (2018.01); A61P 31/04 (2018.01)]

19 Claims

1. An endothelial progenitor cell-derived exosome, wherein the endothelial progenitor cell-derived exosome comprises one or more modifications that enhance expression of an miR-126 microRNA in the endothelial progenitor cell-derived exosome; and further wherein at least one of the one or more modifications comprises introduction of a heterologous nucleotide sequence that comprises, consists essentially of, or consists of, and/or that encodes, one or more of SEQ ID NOs: 1 and/or 3 into an endothelial progenitor cell from which the endothelial progenitor cell-derived exosome is derived, whereby the expression of the miR-126 microRNA in the endothelial progenitor cell-derived exosome is enhanced relative to the expression of the miR-126 microRNA in an endothelial progenitor cell-derived exosome isolated from an untreated endothelial progenitor cell-derived exosome.